Financing ·
Radiopharm Theranostics Limited closed a registered direct offering of 1,281,646 American Depositary Shares (ADSs) at…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics Limited closed a registered direct offering of 1,281,646 American Depositary Shares (ADSs) at $3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The company concurrently issued unregistered warrants to purchase up to 1,281,646 ADSs at an exercise price of $3.79 per ADS, expiring July 31, 2029. Additionally, the company secured firm commitments for approximately A$6.7 million (US$4.7 million) from Australian institutional investors in a private placement and plans a Share Purchase Plan to raise up to A$6 million (US$4.2 million). These transactions are subject to shareholder approval at an extraordinary general meeting expected around September 11, 2026. The company intends to use the proceeds to fund its RAD101 Phase 3 study, complete RAD 204 dose escalation, and support other therapeutic programs. Radiopharm Theranostics is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic applications.